Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
H101 is an E1B55KD deleted oncolytic adenovirus, which is the first and only adenovirus to be
approved by China State Food and Drug Administration in 2005 for treating head and neck
cancer. The objective of this phase II clinical trial is to investigate the safety and
efficacy of H101 combined with PD-1 inhibitor Camrelizumab in patients with
non-muscle-invasive bladder cancer who failed BCG therapy.